{
    "clinical_study": {
        "@rank": "67274", 
        "arm_group": {
            "arm_group_label": "ECT and Treatment Resistant Depression", 
            "description": "Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two [18F]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments."
        }, 
        "biospec_descr": {
            "textblock": "Whole blood, plasma and serum samples will be kept for analysis of genotype, peripheral\n      inflammatory markers and protein binding."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore whether electroconvulsive therapy (ECT) accidentally\n      leads to a side effect of brain inflammation. Patients with treatment resistant depression\n      who are planning to take ECT will be subsequently approached to participate in the study."
        }, 
        "brief_title": "Inflammation and Electroconvulsive Therapy", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The first scan will take place before the first ECT session. The second scan will occur\n      after a minimum of six ECT sessions (average 2.5 weeks). Secondary measures will include\n      mood symptom severity, neurocognitive measures, peripheral inflammatory markers and TSPO\n      genotype.\n\n      The hypothesis is that neuroinflammation will be increased by ECT.\n\n      There will be no alterations to standard care of depressed patients due to participation in\n      the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  stable physical health\n\n          -  diagnosis of non-psychotic, non-catatonic, major depressive disorder, either unipolar\n             or bipolar and a non-response to at least three clinical trials at appropriate dose\n             of antidepressant medication from at least three different pharmacological classes\n\n          -  at least a 17 on the17-item HDRS despite taking antidepressant treatment prior to ECT\n\n          -  have not received ECT within the last 12 weeks\n\n        Exclusion Criteria:\n\n          -  currently pregnant\n\n          -  current substance abuse or dependence\n\n          -  neurological or unstable medical illness\n\n          -  use of anti-inflammatory drugs within the past month\n\n          -  diazepam or other benzodiazepine use within the past month, except for lorazepam and\n             clonazepam"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Community and tertiary care clinic"
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095639", 
            "org_study_id": "074-2012"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5T 1R8"
                }, 
                "name": "Centre for Addiction and Mental Health"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Does Electroconvulsive Therapy Cause Neuroinflammation? An [18F]FEPPA Positron Emission Tomography Study in Treatment Resistant Depression", 
        "overall_official": {
            "affiliation": "Research Imaging Centre, Centre for Addiction and Mental Health", 
            "last_name": "Jeffrey H Meyer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participants will have one [18F]FEPPA PET scan before they start ECT and a second PET scan on average after 2.5 weeks of ECT", 
            "measure": "Change in translocator protein distribution volume (TSPO Vt) measured by [18F]FEPPA PET", 
            "safety_issue": "No", 
            "time_frame": "Baseline scan and a second PET scan after an expected average time of 2.5 weeks of ECT treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095639"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre for Addiction and Mental Health", 
            "investigator_full_name": "Jeff Meyer", 
            "investigator_title": "Program Head, Neurochemical Imaging for Mood Disorders", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Scores on the 17-item HDRS will be taken at the time of the PET scan (baseline and post-ECT) to assess whether the magnitude of change in TSPO distribution volume is associated with changes in symptom severity.", 
                "measure": "17-item Hamilton Depression Rating Scale (HDRS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after average 2.5 weeks of ECT treatment"
            }, 
            {
                "description": "Neurocognitive measures will be take at baseline and post-ECT to assess whether TSPO Vt is related to neurocognitive function. Neurocognitive battery includes:\nAutobiographical Memory Interview-Short Form (AMI-SF) Rey Auditory Verbal Learning Test (RAVLT) Wisconsin Card Sorting Test Comprehensive Trail Making Test Weschler Adult Intelligence Scale-Digit Symbol Subtest Stroop Color and Word Test Brief Visuospatial Memory Test Boston Naming Test Judgement of Line Orientation Weschler Test of Adult Reading", 
                "measure": "Neurocognitive Battery", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after average 2.5 to 5 weeks of ECT treatment"
            }, 
            {
                "description": "To explore whether peripheral and central inflammation are related markers of peripheral inflammation (TNF-alpha, IL-6, CRP and IL-1beta) will be measured and correlated to brain TSPO Vt.", 
                "measure": "Peripheral Inflammatory Markers", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after average 2.5 to 5 weeks of ECT treatment"
            }
        ], 
        "source": "Centre for Addiction and Mental Health", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre for Addiction and Mental Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}